Skip to main content
. Author manuscript; available in PMC: 2017 Jul 11.
Published in final edited form as: Adv Pharmacol. 2014 Aug 22;71:203–243. doi: 10.1016/bs.apha.2014.06.002

Figure 5.

Figure 5

Rituximab increases survival in the rat model of CNS lymphoma. Rats with MRI-confirmed MC116 CNS lymphoma were randomized to treatment groups and followed for survival. The Kaplan–Meier survival curves show that methotrexate (MTX) was ineffective in this model (P=0.18), whereas all rituximab (RTN) groups improved survival compared with control (RTN BBBD [blood–brain barrier disruption], P=0.013; RTN +MTX BBBD, P=0.0042; RTN IV [intravenous], P=0.0049). Reprinted from Muldoon, Lewin, et al. (2011).